TNFRSF17 and Miyoshi myopathy: Anti-BCMA CAR T-cell therapy has demonstrated a significant impact on the treatment of patients with MM; however, this novel therapeutic approach is associated with a distinct spectrum of immune-mediated adverse events, such as MAS-like.